Jazz Pharmaceuticals announced the promotion of current President and Chief Operating Officer Renée Galá as its incoming CEO, succeeding co-founder Bruce Cozadd in August. This leadership transition coincides with executive appointments across QuidelOrtho, Bioptimus, and Becton Dickinson. The wave of senior leadership changes reflects strategic organizational shifts and adaptation amid ongoing industry challenges. Meanwhile, Jazz’s shares and those of partners Ultragenyx and Mereo experienced declines following trial updates.